PharmaShots | Incisive News in 3 Shots

Subscribe Now

RUXCOVID Study

Novartis' Ruxolitinib Fails to Meet its Primary Endpoint in P-lll RUXCOVID Study for COVID-19

Novartis' Ruxolitinib Fails to Meet its Primary Endpoint in P-lll RUXCOVID Study for COVID-19

December 14, 2020

Incyte Initiates P-III RUXCOVID Study Evaluating Jakafi (ruxolitinib) to Treat Patients with COVID-19 Associated Cytokine Storm

Incyte Initiates P-III RUXCOVID Study Evaluating Jakafi (ruxolitinib) to Treat Patients with COVID-19 Associated Cytokine Storm

April 20, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us